A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

被引：2
|
作者：
Chuncharunee, Suporn [1 ]
Kanitsap, Nonglak [2 ]
Suwanban, Tawatchai [3 ]
Khuhapinant, Archrob [4 ]
Uaprasert, Noppacharn [5 ]
Chansung, Kanchana [6 ]
Rattarittamrong, Ekarat [7 ]
Wongkhantee, Somchai [8 ]
Siritanaratanakul, Noppadol [4 ]
Norasetthada, Lalita [7 ]
Nakorn, Thanyaphong Na [5 ]
Charnwiboonsri, Chadchai [9 ]
机构：
[1] Mahidol Univ, Ramathibodi Hosp, Dept Internal Med, Bangkok, Thailand
[2] Thammasat Univ, Dept Internal Med, Pathum Thani, Thailand
[3] Rajavithi Hosp, Dept Internal Med, Bangkok, Thailand
[4] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand
[5] Chulalongkorn Univ, Dept Med, Bangkok, Thailand
[6] Khon Kaen Univ, Dept Internal Med, Khon Kaen, Thailand
[7] Chiang Mai Univ, Dept Internal Med, Chiang Mai, Thailand
[8] Khonkaen Reg Hosp, Dept Internal Med, Khon Kaen, Thailand
[9] Roche Thailand Ltd, Med Dept, Bangkok, Thailand
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5543.5543
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5543
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"
    Sebert, Marie
    Chaffaut, Cendrine
    Thepot, Sylvain
    Orvain, Corentin
    Cluzeau, Thomas
    Loschi, Michael
    Peterlin, Pierre
    Chevallier, Patrice
    d'Aveni, Maud
    Rubio, Marie-Therese
    Rauzy, Odile Beyne
    Huynh, Anne
    Charbonnier, Amandine
    Fegueux, Nathalie
    Fossard, Gaelle
    N'guyen-Quoc, Stephanie
    Park, Sophie
    Sapena, Rosa
    Chermat, Fatiha
    Ades, Lionel
    Chevret, Sylvie
    Fenaux, Pierre
    Robin, Marie
    BLOOD, 2021, 138 : 1842 - +
  • [32] The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study
    Liang, Ying
    Cao, Changan
    Zhu, Cheng
    Wang, Chuanyue
    Zhang, Congpei
    Dong, Fang
    Yang, Fude
    Deng, Hong
    Yu, Jingjie
    Tang, Jisheng
    Su, Lei
    Xin, Limin
    Hong, Ling
    Gao, Minglong
    Tang, Muni
    Xie, Shiping
    Lu, Shuiping
    Liu, Tiebang
    Xu, Xiaojin
    Wang, Xijin
    Li, Xuanzi
    Wang, Xueyi
    Li, Yi
    Zhang, Yong
    Chen, Zhiyu
    Yu, Xin
    ASIA-PACIFIC PSYCHIATRY, 2016, 8 (03) : 241 - 244
  • [33] Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain
    Yoon, Do Heum
    Bin, Seong-Il
    Chan, Simon Kin-Cheong
    Chung, Chun Kee
    In, Yong
    Kim, Hyoungmin
    Lichauco, Juan Javier
    Mok, Chi Chiu
    Moon, Young-Wan
    Ng, Tony Kwun-Tung
    Penserga, Ester Gonzales
    Shin, Dong Ah
    You, Dora
    Moon, Hanlim
    BMC MUSCULOSKELETAL DISORDERS, 2017, 18
  • [34] Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain
    Do Heum Yoon
    Seong-Il Bin
    Simon Kin-Cheong Chan
    Chun Kee Chung
    Yong In
    Hyoungmin Kim
    Juan Javier Lichauco
    Chi Chiu Mok
    Young-Wan Moon
    Tony Kwun-Tung Ng
    Ester Gonzales Penserga
    Dong Ah Shin
    Dora You
    Hanlim Moon
    BMC Musculoskeletal Disorders, 18
  • [35] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [36] Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.
    Jabbour, Elias J.
    Daver, Naval G.
    Dong, Tina
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Ghanem, Hady
    Faderl, Stefan
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2012, 120 (21)
  • [37] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Haase, D.
    Hankin, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M.
    Attie, K.
    HAEMATOLOGICA, 2015, 100 : 192 - 192
  • [38] Karyotype evolution in patients with MDS and isolated deletion (5q) with IPSS low or intermediate-1-risk: Results of LeMon5 study
    Shirneshan, K.
    Platzbecker, U.
    Nolte, F.
    Giagounidis, A.
    Goetze, K.
    Braulke, F.
    Schanz, J.
    Germing, U.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 233 - 234
  • [39] ACE-536 INCREASES HEMOGLOBIN LEVELS IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Hankin, M.
    Wilson, D.
    Sherman, M.
    Attie, K.
    HAEMATOLOGICA, 2014, 99 : 500 - 500
  • [40] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Haase, D.
    Hankin, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M.
    Attie, K.
    LEUKEMIA RESEARCH, 2015, 39 : S25 - S25
12345